BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9482115)

  • 1. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers.
    Wang Q; Driouch K; Courtois S; Champème MH; Bièche I; Treilleux I; Briffod M; Rimokh R; Magaud JP; Curmi P; Lidereau R; Puisieux A
    Oncogene; 1998 Feb; 16(5):677-9. PubMed ID: 9482115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
    Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
    Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
    Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
    Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues.
    Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M
    Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of TSG101 transcript abnormalities in human cancers.
    Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D
    Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TSG101 and breast cancer: a correctly named tumor-suppressor gene?].
    Bénard J; Ahomadégbé JC
    Bull Cancer; 1997 Dec; 84(12):1141-2. PubMed ID: 9587367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of mutations within ST7 gene in tumour-derived cell lines and primary epithelial tumours.
    Brown VL; Proby CM; Barnes DM; Kelsell DP
    Br J Cancer; 2002 Jul; 87(2):208-11. PubMed ID: 12107844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers.
    Chang JG; Su TH; Wei HJ; Wang JC; Chen YJ; Chang CP; Jeng CJ
    Br J Cancer; 1999 Feb; 79(3-4):445-50. PubMed ID: 10027311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cellular TSG101 protein in multiple human breast cancer cell lines.
    Zhong Q; Chen CF; Chen Y; Chen PL; Lee WH
    Cancer Res; 1997 Oct; 57(19):4225-8. PubMed ID: 9331081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.
    Turpin E; Dalle B; de Roquancourt A; Plassa LF; Marty M; Janin A; Beuzard Y; de Thé H
    Oncogene; 1999 Dec; 18(54):7834-7. PubMed ID: 10618725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.
    Hosokawa Y; Nagai E; Seto M
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
    Anbazhagan R; Bornman DM; Johnston JC; Westra WH; Gabrielson E
    Cancer Res; 1999 Jul; 59(14):3363-4. PubMed ID: 10416594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of rearrangements in the BRCA2 gene in human cancers.
    Chin SF; Wang Q; Puisieux A; Caldas C
    Br J Cancer; 2001 Jan; 84(2):193-5. PubMed ID: 11161375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
    Majumdar S; Diamandis EP
    Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of ST7 gene alterations in human cancer.
    Dong SM; Sidransky D
    Clin Cancer Res; 2002 Sep; 8(9):2939-41. PubMed ID: 12231539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
    Magdinier F; Ribieras S; Lenoir GM; Frappart L; Dante R
    Oncogene; 1998 Dec; 17(24):3169-76. PubMed ID: 9872332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Identification of the differentially expressed genes between primary breast cancer and paired lymph node metastasis through combining mRNA differential display and gene microarray].
    Feng YM; Gao G; Zhang F; Chen H; Wan YF; Li XQ
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(39):2749-55. PubMed ID: 17199993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
    Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
    Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of p51 alteration in human ovarian cancer.
    Shinozaki H; Okamoto A; Shimizu K; Saito M; Yokota J; Ochiai K
    Int J Oncol; 2001 Mar; 18(3):549-52. PubMed ID: 11179485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.